NAS:CALA (USA) Also Trade In: Germany
Calithera Biosciences Inc $ 2.98 -0.12 (-3.87%)
Warning! GuruFocus has detected 1 Severe warning sign with CALA. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for CALA (Calithera Biosciences Inc) from 2014 to Jan 20 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Calithera Biosciences stock (CALA) PE ratio as of Jan 20 2021 is 0. More Details
Calithera Biosciences PE Ratio (TTM) Historical Data
View and export this data going back to 2014. Start your Free Trial
Calithera Biosciences PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:RAPT NAS:BSTC NAS:MRUS NAS:MCRB NAS:AGEN NAS:FULC NAS:STSA NAS:CPRX NAS:XBIT NAS:PTGX OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm is functioned through the region of US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.